MAIA Biotechnology, Inc. (MAIA)
1.34
-0.03
(-2.19%)
USD |
NYAM |
Sep 03, 10:42
MAIA Biotechnology Research and Development Expense (TTM) : 17.40M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.40M |
| March 31, 2026 | 14.87M |
| December 31, 2025 | 14.55M |
| September 30, 2025 | 15.66M |
| June 30, 2025 | 11.99M |
| March 31, 2025 | 10.95M |
| December 31, 2024 | 10.09M |
| September 30, 2024 | 10.84M |
| June 30, 2024 | 10.81M |
| March 31, 2024 | 11.38M |
| Date | Value |
|---|---|
| December 31, 2023 | 11.29M |
| September 30, 2023 | 10.02M |
| June 30, 2023 | 9.771M |
| March 31, 2023 | 9.388M |
| December 31, 2022 | 9.218M |
| September 30, 2022 | 8.249M |
| June 30, 2022 | 6.923M |
| March 31, 2022 | 5.311M |
| December 31, 2021 | 3.497M |
| September 30, 2021 | 2.139M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Regeneron Pharmaceuticals, Inc. | 5.748B |
| TG Therapeutics, Inc. | 225.80M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |